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Purpose of vaccine summary 
• Updated Advisory Committee on Immunization Practices (ACIP) recommendations 
for the use of human papillomavirus (HPV) vaccine, December 16, 2016. 
• Revised Iowa VFC Program recommendations for the use of HPV vaccine effective 
December 16, 2016. 
 
Human Papillomavirus (HPV) Vaccine Recommendations 
Food and Drug Administration (FDA)  
• On October 7, 2016, the FDA approved Gardasil 9 to be used as a two-dose 
schedule for individuals 9 through 14 years of age. 
• On December 14, 2015, the FDA expanded its approval for the use of Gardasil 9 in 
males 16 through 26 years of age. 
• On December 10, 2014, the FDA approved Gardasil 9 for  
o females 9 through 26 years of age, to prevent cervical, vulvar, and anal 
cancers, precancerous genitoanal lesions and genital warts due to HPV types 
6, 11, 16, 18, 31, 33, 45, 52, and 58.  
o males 9 through 15 years of age to prevent anal cancer and precancerous 
lesions and genital warts due to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 
58. 
• On October 16, 2009, the FDA approved Cervarix for use in females 10 through 25 
years of age. 
• On October 16, 2009, the FDA approved the use of Gardasil in males. 
• In June 2006, the FDA approved, Gardasil for females 9 through 26 years of age, to 
prevent cervical cancer, precancerous genital lesions and genital warts due to HPV 
types 6, 11, 16 and 18. 
 
Advisory Committee on Immunization Practices (ACIP) 
• HPV is routinely recommended for adolescents at 11 or 12 years of age. 
• The series may be started as young as 9 years of age. The series is also 
recommended for females 13 through 26 years of age and males 13 through 21 
years of age who have not been vaccinated previously. Males 22 through 26 years of 
age may be vaccinated. 
• Any brand may be given to females from 9 through 26 years of age.  
• Gardasil and Gardasil 9 should be given to males 9 through 21 years of age and may 
be given to males 22 through 26 years of age. (Cervarix should not be used in 
males). 
• Healthy adolescents who begin the HPV series between 9 through 14 years of age 
may complete the 2-dose series by administering the second dose at least 6 to 12 
months after the first dose. 
• Immunocompromised individuals 9 through 26 years of age should complete the 3-
dose series at 0, 1-2, and 6 month intervals. 
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• Healthy adolescents and young adults who begin the series between 15 through 26 
years of age should complete the 3-dose series at 0, 1-2, and 6 month intervals. 
  
VFC Resolution 
The VFC Program follows the ACIP recommendations for the use of HPV vaccine for VFC 
eligible children 9 through 18 years of age.   
 
Recommended Schedule for HPV Vaccine 
The 2-dose schedule should be administered to healthy adolescents who begin the HPV 
vaccine series between 9 through 14 years of age: 
 1st dose:   initial dose 
 2nd dose: 6 to 12 months after the first dose 
 
The 3-dose schedule should be administered to adolescents and young adults who begin the 
series between 15 through 26 years of age, and to immunocompromised individuals 
regardless of when they started the series: 
 1st dose:  initial dose 
 2nd dose:  1 to 2 months after the first dose 
 3rd dose: 6 months after the first dose, and at least 12 weeks after the second 
dose 
 
HPV vaccine can be administered at the same visit as other routinely recommended 
adolescent vaccines such as Tdap, MCV4, meningococcal B, and influenza. 
 
Syncope can occur after vaccination, most commonly among adolescents and young adults.  
To avoid serious injury related to a syncopal episode, vaccine providers should consider 
observing patients for 15 minutes after they are vaccinated. 
 
Interrupted Vaccine Schedules 
If the vaccine schedule is interrupted the vaccine series does not need to be restarted.  
 
Minimum Intervals for HPV Vaccine 
 Minimum Age:  9 years 
  
 2-dose schedule 
  Dose 1 to 2:  5 calendar months 
 
 3-dose schedule 
 Dose 1 to 2:  4 weeks 
 Dose 2 to 3:  12 weeks  
 Overall, there must be at least 5 calendar months between doses 1 and 3. 
 
Recommended Dosage 
Each dose of HPV vaccine is 0.5mL, administered intramuscularly.  Refer to package insert.  
 
Vaccine Storage and Handling 
Store refrigerated at 2 to 8oC (36 to 46oF).  Do not freeze.  Protect from light.  Refer to 
package insert. 
Iowa Department of Public Health 
Division of Acute Disease Prevention, Emergency Response and Environmental Health 
Immunization Program 




HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a 
positive Hybrid Capture II ® high risk test, or genital warts. 
 
Vaccine recipients should be advised that data from clinical trials do not indicate the vaccine 
will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital 
warts.  Vaccination of these females would provide protection against infection with vaccine 
HPV types not already acquired. 
 
Immunocompromised persons 
HPV vaccine is not a live vaccine and can be administered to persons who are 
immunocompromised as a result of disease or medication; however, the immune response 
to the vaccine might be less than that in persons who are immunocompetent.  
 
Vaccination during pregnancy 
HPV vaccines are not recommended for use during pregnancy.  The vaccine has not been 
causally associated with adverse outcomes of pregnancy or adverse events to the 
developing fetus.  However, data on vaccination in pregnancy are limited.  Until further 
information is available, initiation of the vaccine series should be delayed until after 
completion of the pregnancy.  If a woman is found to be pregnant after initiating the 
vaccination series, completion of the vaccine series should be delayed until after completion 
of the pregnancy.  If a vaccine dose has been administered during pregnancy, there is no 
indication for any intervention.  Merck has established a registry for women who receive 
HPV 9 vaccine in pregnancy; patients and health-care providers are encouraged to report 
any exposure to HPV 9 vaccine during pregnancy by calling (800) 986-8999.  
 
Lactating women  
Lactating women can receive HPV vaccine.  
 
Precautions and Contraindications 
 Acute illness 
HPV vaccines can be administered to persons with minor acute illnesses 
(e.g., diarrhea or mild upper respiratory tract infections, with or without 
fever).  Vaccination of persons with moderate or severe acute illnesses 
should be deferred until after the illness improves. 
 
 Immediate hypersensitivity or allergy to vaccine components 
Bivalent and quadrivalent HPV vaccine is contraindicated for persons with a 
history of immediate hypersensitivity to any vaccine component.  The 
prefilled syringes of bivalent HPV vaccine should not be used in persons with 
anaphylactic latex allergy because syringes have latex in the rubber stopper.  
Bivalent HPV vaccine single dose vials contain no latex.   
 
School Requirements  
The role of school laws is to assist in the removal of barriers to vaccine and to prevent the 
transmission of disease in school settings.  HPV vaccine is not required for school 
enrollment. 
 
HPV 9 CPT Code: 90651 
